Diabetes

New research shows that independent of other forms of physical activity, biking is associated with reduced mortality rates among adults with diabetes.

Catlin Dennis, MPH, describes the challenges socially and medically vulnerable youth with diabetes and their families faced during the COVID-19 pandemic.

Michelle Litchman, PHD, FNP-BC, FAANP, FADCES, an assistant professor at the College of Nursing at the University of Utah, describes the results of a study that looked at diabetes technology use and online peer support systems among Spanish-speaking patients. Findings showed that when these 2 interventions are used in conjunction, a positive feedback loop forms.

Patients with prediabetes are at significantly higher risk of major cardiovascular events than those who have never had high blood sugar.

David McIntyre, MD, FRACP, describes different methods of diagnosing gestational diabetes around the world.

A statement from the makers of the SGLT2 inhibitor empagliflozin suggests the benefits in heart failure with preserved ejection fraction (HFpEF) are significant.

The FDA issued a Complete Response Letter, halting Provention Bio's type 1 diabetes prevention drug.

Vaccination rates among Medicaid beneficiaries remain low; Walmart introduces a less expensive insulin option; Moderna says its vaccine is effective against the delta variant.

Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, outlines the benefits of sotagliflozin for individuals with type 2 diabetes and chronic kidney disease or heart failure.

The study was launched the same month as the first US approval of a sodium-glucose co-transporter 2 inhibitor, and the failure to include a drug from this class was viewed by a commentator as a weakness of GRADE.

Sanofi gave up rights to develop the glucagon-like peptide 1 receptor agonist last year after a change in strategy.

Catlin Dennis, MPH, describes her research on the impacts of COVID-19 on Oregon’s most medically and socially vulnerable youth with diabetes.

Bobeck Modjtahedi, MD, describes how Kaiser Permanente leveraged its telehealth resources to provide care to those with diabetic retinopathy (DR) throughout the COVID-19 pandemic.

Michelle Litchman, PHD, FNP-BC, FAANP, FADCES, an assistant professor at the College of Nursing at the University of Utah, highlights her research on the benefits of concurrent continuous glucose monitoring and online peer support groups for Spanish-speaking patients with diabetes.

David McIntyre, MD, FRACP, gives an overview of his talk "Diagnosis and Management of Diabetes in Pregnancy During the COVID-19 Pandemic," to be presented at the American Diabetes Association's (ADA) 81st Scientific Sessions.

The once-weekly therapy is also being studied in nonalcoholic steatohepatitis and heart failure with preserved ejection fraction and obesity.

Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA), previews sessions to be presented at the ADA's 81st Scientific Sessions.

This article demonstrates that few patient encounters with indicators of need for diabetes self-management education result in a provider referral to the service.

A recent decline in the proportion of adults with diabetes achieving glycemic control may contribute to more diabetes-related health issues and deaths across America.

Human synthetic insulin may offer low-cost, effective treatment for certain patients with diabetes and financial constraints.

The UK analysis came from a larger study that examined the effects of a liquid total diet replacement program to induce remission in type 2 diabetes (T2D).

The FDA said it is the first approved drug for chronic weight management in adults with general obesity or overweight since 2014.

Here is some of the latest news in diabetes from our sister publication Pharmacy Times®.

When drug developers were forced to conduct cardiovascular outcomes trials for SGLT2 inhibitors, they found a surprise: the drugs created for type 2 diabetes (T2D) had strong benefits for heart failure. And the same has proven true in sotagliflozin.

There is a role for pharmacists and pharmacy quality measures in addressing the public health challenge of diabetes, according to speakers at a recent virtual meeting this week.